ClinicalTrials.gg
Active, not recruitingNCT06809530Updated Oct 13, 2026

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

A Phase 1/2 interventional study of QL1706 (bispecific antibody targeting PD-1 and CLTA-4) and Pemetrexed (Alimta) in Leptomeningeal Metastasis, Pemetrexed and PD-1 Inhibitor, sponsored by Guangzhou Medical University. Active, not recruiting at 5 sites in China. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Guangzhou Medical University · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 13, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 54 studies in Meningeal Carcinomatosis with a site in China — 29 open to participants now, 34 under way, none of them phase 3. Meningeal Carcinomatosis · China.

Planned enrollment
23rd of 46
39 · median 39
Started
2025
with 10 others
Phase 1/2
8 of 54
4 open now
Primary completion
2026-12
later than 12 of 33 live
Registered
39th of 54
by date
Lead sponsor
8 of 54
Guangzhou Medical University

Among the 54 studies in Meningeal Carcinomatosis with a site in China, this one is the 23rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 11 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 12 of the 33 other live ones, and was the 39th registered.

Meningeal Carcinomatosis

146 studies on the registry are indexed under Meningeal Carcinomatosis; 48 are open to participants now.

Browse Meningeal Carcinomatosis studies →

Open to participants now

29 of the 54 studies in Meningeal Carcinomatosis with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 33 Meningeal Carcinomatosis studies recruiting now, 21 (64%) set no upper age limit and 10 (30%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Meningeal Carcinomatosis with a site in China, or all of them as a file.
02

Study summary

This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.

Read the detailed description

This study is a prospective, single-arm, phase I/II clinical trial evaluating intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with the bispecific antibody QL1706) in combination with pemetrexed for the treatment of leptomeningeal metastasis.

Intrathecal pemetrexed is administered twice weekly for 2 weeks (induction phase), then weekly for 4 weeks (consolidation phase), and monthly thereafter (maintenance phase). Intrathecal QL1706 (a co-formulation of separate anti-PD-1 and anti-CTLA-4 antibodies) is given every two weeks during the six-week (induction and consolidation phase), followed by monthly injections in the maintenance phase, until disease progression or death.

The primary objectives are to determine the recommended dose of intrathecal QL1706 in combination with pemetrexed and to assess safety based on the incidence of treatment-related adverse events. Clinical response rate, disease control rate, and overall survival are also evaluated. Patients undergo cerebrospinal fluid and blood specimen collection to evaluate potential clinical, molecular, and/or immune predictors of treatment efficacy and safety.

03

Conditions studied

  • Leptomeningeal Metastasis
  • Pemetrexed
  • PD-1 Inhibitor
  • CTLA4
  • Solid Tumors

Keywords

  • Leptomeningeal metastasis
  • dual checkpoint inhibitor
  • pemetrexed
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of solid tumors; Cerebrospinal fluid cytopathology is positive.
  2. Male or female aged between 21 and 75 years; Normal liver and kidney function; WBC≥4000/mm3, Plt≥100000/mm3.
  3. No history of severe nervous system disease; No severe dyscrasia.

Exclusion criteria

Exclusion Criteria:

  1. Any evidence of nervous system failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy on imaging, and Glasgow Coma Score less than 11.
  2. Any evidence of extensive and lethal progressive systemic diseases without effective treatment.
  3. A history of or AIDS, acute or chronic or C infection, previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy; or ongoing disease that required systemic treatment in the past 2 years.
  4. Patients with poor compliance or other reasons that were unsuitable for this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Intrathecal Dual Checkpoint Inhibition in Combination with Pemetrexed

    This study is a prospective, single-arm, Phase I/II clinical trial. The primary objectives were to determine the recommended dose of intrathecal dual checkpoint inhibitor (PD-1 and CTLA-4, QL1706) in combination with pemetrexed and safety based on the incidence of treatment-related adverse events. Clinical response rate (CRR), disease control rate (DCR) and overall survival (OS) are also evaluated. Patients will have cerebrospinal fluid (CSF) and blood specimen collection for the evaluation of predictors (clinical, molecular, and/or immune) of the efficacy and safety of this regimen.

    Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) · Drug: Pemetrexed (Alimta)

Interventions

  • DrugQL1706 (bispecific antibody targeting PD-1 and CLTA-4)

    Drug page: Iparomlimab/TuvonralimabStudies of Iparomlimab/TuvonralimabIparomlimab/Tuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intrathecal injection of PD-1/CTLA-4 bispecific antibody was administered every 2 weeks for 6 weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.

  • DrugPemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pemetrexed (Alimta, Eli Lilly and Company) was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.

06

What researchers measure

Primary outcomes

  1. RP2D

    The recommended phase II dose. The dose limiting toxicity was defined as ≥ grade 3 neurological toxicities (e.g.,meningitis) or other grade 4 toxicity.

    Time frame: Dose limiting toxicity was assessed during the first 6 weeks after the first intrathecal administration.

  2. Incidence of treatment-related adverse events

    The incidence of treatment-related adverse events were measured for determining tolerability and safety. Adverse events (AEs) are evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). Events of grade 3-5 are defined as moderate and severe adverse events.

    Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.

Other outcomes

  1. Clinical response rate

    The response assessment in neuro-oncology criteria (RANO) proposal for response criteria of leptomeningeal metastasis was used to assess the clinical response in this study.

    Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months

  2. Disease control rate (DCR)

    Disease control rate was defined as proportion of patients achieving clinical response or stable disease. Clinical response and stable disease were determined based on the RANO proposal evaluation criteria which have been established and published on Neuro Oncol.

    Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.

  3. Overall survival(OS)

    Overall survival was recorded since the date of patient enrollment. All patients were followed up until death or the end of the study.

    Time frame: From the enrollment of this study until date of death from any cause, whichever came first, or the last follow-up, assessed up to 6 months.

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2025
First posted
Feb 5, 2025
StartActual
Mar 17, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Sep 1, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
34→39
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Enrollment 34→39

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06809530
Lead sponsor
Guangzhou Medical University
Responsible party
Zhenyu Pan (Professor, Guangzhou Medical University) — Principal investigator
First posted
Feb 5, 2025
Start date
Mar 17, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Zhenyu Pan, PhD,MD
principal investigator · Jinshan Hospital Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iparomlimab/Tuvonralimab

Start the discussion